UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/590,889	06/04/2007	Peter Svete	33668US-PCT	3731
	7590 03/16/201 - LUEDEKA, NEELY	EXAMINER		
P.O. BOX 1871		RAO, SAVITHA M		
Knoxville, TN	5/901		ART UNIT	PAPER NUMBER
			1614	
			MAIL DATE	DELIVERY MODE
			03/16/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/590,889	SVETE ET AL.	
Examiner	Art Unit	

	SAVITHA RAO	1614	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress
THE REPLY FILED <u>09 March 2010</u> FAILS TO PLACE THIS AP	PLICATION IN CONDITION FOR A	ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following rapplication in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:	the same day as filing a Notice of A eplies: (1) an amendment, affidavi al (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	which places the r (3) a Request
<ul> <li>a) The period for reply expiresmonths from the mailing</li> <li>b) The period for reply expires on: (1) the mailing date of this Adno event, however, will the statutory period for reply expire land</li> </ul>	dvisory Action, or (2) the date set forth ter than SIX MONTHS from the mailing	g date of the final rejection	on.
Examiner Note: If box 1 is checked, check either box (a) or (I MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extruder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	). on which the petition under 37 CFR 1.1 ension and the corresponding amount of hortened statutory period for reply origi	36(a) and the appropriat of the fee. The appropriat nally set in the final Offic	e extension fee ate extension fee the action; or (2) as
2. The Notice of Appeal was filed on <u>09 March 2010</u> . A brief date of filing the Notice of Appeal (37 CFR 41.37(a)), or ar Since a Notice of Appeal has been filed, any reply must be <u>AMENDMENTS</u>	ny extension thereof (37 CFR 41.37	7(e)), to avoid dismiss	al of the appeal.
3.  The proposed amendment(s) filed after a final rejection, be (a) They raise new issues that would require further cord (b) They raise the issue of new matter (see NOTE below (c) They are not deemed to place the application in bett appeal; and/or (d) They present additional claims without canceling a content of the content	nsideration and/or search (see NOT w); er form for appeal by materially rec	E below); ducing or simplifying th	
NOTE: See Continuation Sheet. (See 37 CFR 1.174. The amendments are not in compliance with 37 CFR 1.125. Applicant's reply has overcome the following rejection(s):  Newly proposed or amended claim(s) would be all non-allowable claim(s).	16 and 41.33(a)). 11. See attached Notice of Non-Col	mpliant Amendment (l	,
7.  For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proved the status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: <u>7-10</u> . Claim(s) rejected: <u>1-6,18 and 19</u> . Claim(s) withdrawn from consideration:		l be entered and an e	xplanation of
<ul> <li>AFFIDAVIT OR OTHER EVIDENCE</li> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ul>	before or on the date of filing a No sufficient reasons why the affidavi	otice of Appeal will <u>not</u> t or other evidence is	be entered necessary and
<ol> <li>The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary</li> </ol>	vercome <u>all</u> rejections under appea and was not earlier presented. Se	ll and/or appellant fail ee 37 CFR 41.33(d)(1	s to provide a ).
<ul> <li>10.  The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER</li> <li>11.  The request for reconsideration has been consideration because:</li> <li>See Continuation Sheet.</li> </ul>	ered but does NOT place the applic	•	
<ul><li>12. ☐ Note the attached Information <i>Disclosure Statement</i>(s). (</li><li>13. ☐ Other:</li></ul>	P1O/SB/08) Paper No(s)		
/Ardin Marschel/ Supervisory Patent Examiner, Art Unit 1614	/SAVITHA RAO/ Examiner, Art Unit 1614		

## **Continuation Sheet (PTOL-303)**

Application No.

Continuation of 3. NOTE: The amended claims 1,7 and 18 submitted on 03/09/2010 add new limitations that ultimately change claim scope and would require new searching. Specifically, in claims 1 and 18 the newly added limitations "a tablet core wherin the tablet core comprises" adds in the new limitation which narrows the instant claim in terms of the location of the active ingredient. In addition, applicant has converted the previously dependent claim 7 to an independent format in the amendment filed 03/09/2010 adding further limitations where in the active ingredient in the pharmaceutical composition is not specified to be in the tablet core and claims 8-10 are now dependent on the newly amended independent claim 7.

Continuation of 11. does NOT place the application in condition for allowance because: The amended claims 1,7 and 18 submitted on 03/09/2010 add new limitations that ultimately change claim scope and would require new searching. Specifically, in claims 1 and 18 the newly added limitations "a tablet core wherin the tablet core comprises" adds in the new limitation which narrows the instant claim in terms of the location of the active ingredient. In addition, applicant has converted the previously dependent claim 7 to an independent format in the amendment filed 03/09/2010 adding further limitations where in the active ingredient in the pharmaceutical composition is not specified to be in the tablet core and claims 8-10 are now dependent on the newly amended independent claim 7.

Applicants arguments in response to the final rejection mailed on 03/09/2010 has been considered but are deemed unpersuasive. Not considering the newly amended claims 1, 7 and 18 set forth in the response of 03/09/2010 since it will not be entered into the record, none of the arguments presented by the Applicant has been found to be persuasive because they are directed to the proposed amended claims.